Acusphere’s Imagify Hit Hard With FDA Panel Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee cites myriad trial design, safety and efficacy concerns in overwhelmingly negative vote; Acusphere suspends Nasdaq trading.
You may also be interested in...
ECG Contrast Agents May Get Warnings Reduced After Advisory Committee Review
Post-marketing studies requested for Lantheus Medical Imaging's Definity and GE Healthcare's Optison appear to point to lower cardiopulmonary risks than FDA had suspected when it asked the companies to add boxed warnings to the product labels in 2007.
ECG Contrast Agents May Get Warnings Reduced After Advisory Committee Review
Post-marketing studies requested for Lantheus Medical Imaging's Definity and GE Healthcare's Optison appear to point to lower cardiopulmonary risks than FDA had suspected when it asked the companies to add boxed warnings to the product labels in 2007.
FDA Hints At Additional Trials for Acusphere’s Imagify
Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.